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Abstract 
Breast cancer is the second leading cause of cancer related death in women in the US. In 
addition, 20% of all breast cancer cases in the U.S. are from the subtype known as Triple-
Negative Breast Cancer (TNBC), which is the most aggressive and invasive form of the disease.  
This type of breast cancer has the worst prognosis, a decreased survival rate, and no targeted 
therapy. Over the decades, interest in pre- (Neoadjuvant) and post- (Adjuvant) chemotherapy 
treatments, in the management of TNBC has increased.  Therefore, we evaluated the Adjuvant 
and Neoadjuvant effects of anti-telomerases (BIBR 1532 and GV6) with anthracycline-based 
(Doxorubicin) chemotherapy.  In the initial (Neoadjuvant) experiment, MDA-MB-231 (TNBC) 
cells were supplemented with BIBR 1532 (n=4) or GV6 (n=4-6) for 14 days, then exposed to 
Doxorubicin (n=4) for 7 days. In the second (Adjuvant) experiment, cells were primed with 
Doxorubicin for 7 days (n=4) prior to 14 days of BIBR 1532 (n=4) or GV6 (n=4) therapy. The 
Trypan Blue (Gibco) exclusion test was used to assess the viability of the cells.  After 14 days of 
Neoadjuvant treatment with BIBR1532, followed by 7 days of doxorubicin treatment, the cell 
density decreased to 59% of control (p<0.05).  Adjuvant treatment with BIBR 1532 or GV6 had 
limited effect on the proliferation rate of MDA-MB-231 cells.  A higher (p<0.05) percent of dead 
cells was observed in BIBR1532 adjuvant therapy with doxorubicin.  These data indicates that 
neoadjuvant therapy with anti-telomerase in conjunction with anthracycline-based chemotherapy 
does have beneficial effects and warrants further investigation.  
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Introduction 
 
Breast cancer remains a common cause of cancer-associated mortality among females in 
most countries (1).  In 2015, approximately 250,000 new cases of invasive breast cancer will be 
diagnosed in the United States (US), with more than 40,000 cases being fatal, making this 
disease among the leading causes of cancer-related death in women in the US (2).  Currently, 
breast cancers are classified into subclasses based on their ultrastructural morphology and 
receptor status (7).  Cells that overexpress progesterone or estrogen receptors (PR or ER) are 
known as hormone receptor positive, and ones overexpressing the human epidermal growth 
factor 2 receptor (HER2) are known as HER2 positive (7).  These receptors can be expressed 
individually or together on one cell.  To treat these breast cancers, targeted therapies are used 
against the receptors to limit the proliferation of cancerous cells, such as, Trastuzumab, which is 
an antibody-based therapy that specifically targets the HER2 receptor on tumor cells (6).  Breast 
cancer that does not overexpress any of these receptors is known as Triple-Negative Breast 
Cancer (TNBC), it accounts for about 15% of all breast cancer and is the most dangerous form, 
since it has the worst prognosis, a decreased survival rate, and no targeted therapies (1,9).  In the 
US, TNBC is most common in women, who are younger, as well as women of African-American 
or Hispanic heritage, and specifically those who have mutations in the BRCA1 and 2 genes (9).  
Due to the lack of targeted therapy; chemo, radiation, and surgery are the only options available 
for women with this subtype of cancer. Due to its highly invasive and aggressive nature, as well 
as its’ ability to develop resistance, routinely a very high dose of chemo- and radiotherapy are 
utilized. Disappointingly, this approach precipitates a diverse array of side-effects, ranging from 
neutropenia to cardiomyopathies (13, 14).    
 Among these chemotherapy drugs is Doxorubicin, which has been employed extensively 
in the treatment of almost every type of cancer, ranging from leukemia to breast cancer, and has 
shown great effect in its ability to reduce tumor size (15).  Doxorubicin and other anthracyclines 
are drugs that specifically target DNA replication, and they do so by targeting an enzyme known 
as topoisomerase II, which is responsible for reducing torque on the DNA during replication, by 
making double strand breaks and religating the strands. To target this enzyme, anthracyclines use 
their aglycone ring structures to intercalate between the base pairs of DNA, where they stabilize 
the topoisomerase II-DNA complex, which results in double strand breaks and DNA damage (3, 
13).  Though this drug has high effectiveness in cancer therapy, one major drawback is the 
production of free radicals that can build up in and around the cardiac muscle and result in 
cardiomyopathies (13, 14).  In order to reduce the risk of cardiomyopathies, many researchers 
have begun investigating using low-dose extended-period treatment regimens to reduce toxicity 
or combination treatment with other drugs in order to reduce the duration of doxorubicin 
exposure.  A study done by Scheithauer et al., (15), showed that a weekly low-dose regime with 
doxorubicin did not elicit cardiomyopathies, and also had a relatively low generalized toxicity. 
This provides a significant improvement in the clinical outcome over the standard method of 
treatment with larger doses over a short period of time.  Further studies have also shown that a 
reduced dose over a longer period does not diminish the efficacy of the Doxorubicin, but 
significantly reduces the associated risk of cardiomyopathies (14). 
 In recent years, interest in the biology of telomeres and the enzyme telomerase has 
increased in relation to cancer treatment.  The telomeres cap and protect the ends of the 
chromosomes from end-to-end fusion, and are made up of a large number of repetitive sequences 
(TTAGGG in mammals) (10).  In most human somatic cells, these telomeres gradually erode 
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away with each replication, since DNA polymerase I cannot replicate the ends (10).  Once the 
telomeres have eroded to a critical length, the cells go through cellular senescence and cease to 
proliferate (10).  To overcome this end-replication dilemma, some cells activate the enzyme 
telomerase, to lengthen the telomeric sequence. Typically it is repressed in most somatic cells, 
though now it is known to be activated in almost 90% of cancers (1,10), which allows these 
tumor cell lines to elongate their telomeres and achieve immortalization. Recently, the drug 
BIBR1532 (GV1) (4,5) and novel derivatives (GV6) (5) have shown promise in the inhibition of 
the telomerase enzyme, which subsequently induces cellular senescence.   
One drawback though of anti-telomerase therapies is that they require extended treatments in 
order to have notable effects in vivo, since the cells only experience mitotic crisis when their 
telomeres have shortened significantly, which occurs only after a large number of population 
doublings (4,5).  Because of this downside, many researchers have suggested using it in a 
neoadjuvant or adjuvant setting, in order to either sensitize cancer cells to other therapies or 
eliminate remaining cancer cells after the primary treatment (4,5,11).  We thus investigated the 
efficacy of neoadjuvant or adjuvant therapy with the anti-telomerases GV1 (BIBR1532) and 
GV6 in potentiating the effects of anthracycline (Doxorubicin) based chemotherapy.  
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Materials and Methods 
 
Cell line 
Triple-Negative Breast cancer cells (MDA-MB-231) were cultured in RPMI (Life 
Technologies, NY) media supplemented with 10% fetal bovine serum (Innovative Research, MI) 
plus 500uL Antibiotic-Antifungal (Life Technologies, NY) in an incubator set at 37 °C and 5% 
CO2. 
 
Treatment 
Cells were seeded at a density of 0.50x106 cells/ml (T-25) and cultured for 72 hours in 
solvent-free RPMI media to allow cells to acclimatize to culture conditions. The media was then 
supplemented with 10μM GV6, or 10μM BIBR1532 for the neoadjuvant treatment or with 
100nM Dox for adjuvant treatment. After 14 days of neoadjuvant treatment with GV6 or 
BIBR1532, cells were then supplemented with 100nM DOX for 7 days, or after 7 days of DOX 
for the adjuvant treatment, cells were then supplemented with 10μM GV6 or BIBR 1532 for 14 
days. 
                               
 
 
 
 
Figure 1: Chemical Structure of BIBR1532 
 
 
                                                                             Figure 2: Chemical Structure of Doxorubicin 
 
 
Viability Assessment 
At days 7, 14, and 21 of culture in treatment, relative cell densities were evaluated using 
a hemocytometer and the live/dead ratios were calculated using the Trypan Blue Exclusion Test 
(Life Technologies, NY). The number of live/dead cells was estimated by counting and 
averaging the number of cells within a set of four defined grids using an inverted microscope 
(Leica IL; 100X). 
  
Senescence Test 
A commercially available Senescence-Associated β-galactosidase (SA-βGal) Staining Kit 
(Cell Signaling Technology, MA) was used on day 21 to detect the cellular activity of β-
galactosidase at an acidic pH. The average percentage of SA-βGal positive cells per treatment 
was estimated from three independently obtained micrographs using an inverted microscope 
(Olympus, PA; 100X). 
 
Statistical 
Statistical analyses were performed using the Student paired t-test. P<0.05 were 
considered significant. 
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Results 
 
Effects of Neoadjuvant and Adjuvant Anti-Telomerase with Anthracycline on MDA-MB-
231 Proliferation 
 
Exposure to fourteen days of GV1 prior to seven days of doxorubicin treatment, 
significantly (P<0.05) decreased (59%) MDA-MB-231 cell counts in relation to control (Fig 3).  
On the other hand, Neoadjuvant use of GV6 with the doxorubicin had no significant effect on 
proliferation rates in relation to control.  A significant (P<0.05) drop in cell counts was observed 
between days 14 and 21 in neoadjuvant GV1 treatment (doxorubicin exposure), whereas GV6 
neoadjuvant showed no decrease within the same timeframe.   
 
 
Figure 3: Number of viable MDA-MB-231 cells in media supplemented for 14 days with GV1 (BIBR1532) or 
GV6, then supplemented with Doxorubicin for 7 days, at days 7, 14, and 21, as determined by Trypan-Blue 
Exclusion test (n=4).  Cells are expressed relative to control.  Dashed line indicates DOX treatment.  Data are shown 
as Mean  SD; ac are significantly different (p<0.05). 
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In the  adjuvant treatment (Fig 4) approach of seven days of doxorubicin followed by continuous 
fourteen days of GV1/GV6 treatments, there was a significant drop (p<0.05) in cell numbers by 
day 14 of trial (61% with  GV1 and 47% with GV6 compared to control). However, after an 
additional exposure of seven days (day 21 of trial) to GV1, a significant (p<0.05) increase in 
MDA-MB-231 cell counts in relation to control was noted. GV6 trend paralleled that of GV1 
(Fig 4).   
 
 
Figure 4: Number of viable MDA-MB-231 cells in media supplemented with Doxorubicin for 7 days, then GV1 
(BIBR 1532) for 14 days, at days 7, 14, and 21 as determined by Trypan-Blue exclusion test (n=4). Cells counts are 
expressed relative to Control. Dashed line indicates DOX treatment. Data are shown as Mean ± SD; ac are 
significantly different (p<0.05). 
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Percentage of Dead MDA-MB-231 Cells in Neoadjuvant and Adjuvant Anti-telomerase 
Treatment with Doxorubicin 
 
In figure 5, significant increases in dead cell counts were only observed between days 7 
to 14 in the adjuvant GV1 treatment group. 
 
 
Figure 5: Dead MDA-MB 231 cells as a percentage of the total cells supplemented with Neoadjuvant BIBR1532 
and GV6, Adjuvant BIBR1532 and GV6, or Control media, at days 7, 14, and 21.  ab are significantly different 
(P<0.05)  
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Evaluation of Senescence and Proliferation in MDA-MB-231 Cells  
 
In figure 6A, it is apparent that both adjuvant and neoadjuvant GV1/6 significantly 
decreased (p<0.05) the number of replicatively active cells in relation to control, with no notable 
differences between the adjuvant and neoadjuvant groups.  In contrast, Figure 6B demonstrates 
that though both adjuvant and neoadjuvant GV1/6 significantly increased the number of cells 
expressing the senescent phenotype, but with neoadjuvant GV1/6 having a significantly higher 
fold change of senescent cells (p<0.05) than in the adjuvant GV1/6 group.  
 
 
 
Figure 6: Number of (A) non-senescent (replicatively active) cells, and (B) senescent cell/treatment in comparison 
to Control on day 21 of treatment. Data are shown as Mean ± SD.  ab, ac, ad, and ae are significantly different 
(p<0.05) in each panel. 
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Discussion 
 
 TNBC has the worst prognosis, a decreased survival rate, and no targeted therapies, due 
to its lack of the key receptors (ER/PR/HER2) that drive most breast cancer cell proliferation 
(7,9).  Without these receptors, there is no method of targeted therapy to counteract it, and thus 
higher doses of chemo- and radiation therapies are necessary.  Higher doses of these therapies, 
specifically chemotherapy, can have adverse side effects, including cardiomyopathies and 
neutropenia, which can be fatal (3,13,14).  Because of these effects, as well as the lack of 
targeted therapies for TNBC, many researchers have begun exploring new and novel pathways to 
treat TNBC, including targeting of the telomere/telomerase complex, which is responsible for 
cell line immortalization (10).  Drugs targeting the telomeres have notable drawbacks, and thus 
researchers have suggested that they be used in neoadjuvant or adjuvant settings with 
chemotherapy drugs in order to sensitize the cancer cells to the chemo, so smaller doses can be 
used that are less detrimental to patient health (4).  BIBR1532 (GV1) and GV6 are novel anti-
telomerase drugs, and Doxorubicin is a universally employed chemotherapy drug (3,4,13). 
 In this study, MDA-MB-231 breast cancer cells were either treated with neoadjuvant 
GV1 and GV6 then exposed to doxorubicin, or were treated with adjuvant GV1 and GV6 after 
exposure to doxorubicin. Under the neoadjuvant approach, GV1/6 revealed (Figure 3) the most 
notable changes between days 0-7, and days 14-21.  The drop between days 0 -7 correlates with 
initial sensitization of the cells to GV1/6 and this effect is sustained up to day 14.  This is likely 
due to the varying lengths of the telomeres within the cell lines, as noted by Damm et. el. (4), 
which causes the cells to enter replicative senescence in a sequential fashion, thus the initial 
count reduction would be from cells with originally short telomeres entering senescence.  Our 
data indicates that introduction of doxorubicin between days 14 to 21 leads to further drop of 
15% in proliferation rates in the group with GV1 as a neoadjuvant treatment. However, in our 
earlier continuous combination (GV1+doxorubicin) treatment studies (data not shown), a 
decrease of approximately 46% in proliferation rate was observed after 21 days of exposure, 
indicating that the drugs are more potent when given synergistically rather than in a neoadjuvant 
manner for sensitization, though the exact mechanism of this synergism is not known.  Within 
this same timeframe, cell counts are not significantly affected by doxorubicin with neoadjuvant 
GV6, indicating that GV6 is not as effective as GV1.  Though when interpreting 
GV6+doxorubicin synergism data (not shown), it is noted that counts drop to 44% of control by 
day 21, indicating that GV6 and DOX do have a synergistic effect.     
 For these trials, dead cell percentages were also collected for each treatment day, and 
senescence data was collected on day 21.  No increase in dead cell percentages was noted 
compared to control, denoting that the concentrations utilized were not cytotoxic to the cells 
(Figure 5).  The senescence data (Figures 6A and B) shows that both, adjuvant and neoadjuvant 
anti-telomerase therapy are significantly effective at decreasing the number of replicatively 
active cells compared to control.  However, there were significantly more senescent cells in the 
neoadjuvant group compared to adjuvant (p<0.05); implying that a combination of reduction in 
number of actively replicating cells plus increased rate of senescence leads to decreased 
proliferation of tumor cells in all of the experimental groups. 
The data collected here indicates that GV1 is more effective as a neoadjuvant treatment 
with doxorubicin on MDA-MB-231 breast cancer cells, based on its decrease of cell counts on 
day 21 by 40%, which is significantly more than that of GV6 which only reduced cell counts by 
24% by day 21.  In contrast, GV6 appears to be more effective than GV1 in the adjuvant model, 
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since it reduced cell counts more significantly by days 14 and 21 (40% vs 25% and 51% vs 40% 
of control, respectively). This indicates that GV6 becomes significantly more effective in 
inhibiting MDA-MB-231 cancer cell growth when cells are exposed to anthracycline therapy 
prior to GV6 exposure, while GV1 is more effective as pretreatment for cells before they are 
exposed to chemotherapy, indicating possible separate mechanisms of sensitization within the 
cells to the different treatments.  Furthermore, our data suggests that induction of senescence 
rather than apoptosis leads to the reduction in proliferation of MDA-MB-231 breast cancer cells.  
This data is consistent with that collected by Legha et al., (19), who observed significantly 
decreased cardiotoxicity when patients were exposed to continuous low dose doxorubicin 
treatment over a period of 48 or 96 hours, but did not observe reduced antitumor efficacy, 
supporting the idea that continuous low dose anthracycline can retain its toxicity to cancer cells. 
Further, it agrees with Damm et al., (4) who noted BIBR1532’s (GV1) ability to induce the 
senescence phenotype in MDA-MB-231 cells (4,19).     
This study indicates that adjuvant and neoadjuvant anti-telomerase drugs with 
anthracyclines are effective in inhibiting proliferation of TNBC cells, as well as inducing the 
senescence phenotype within these cells.  These results contradict Mauri et al., (16), who found 
that adjuvant and neoadjuvant treatment types were for the most part, similar in their effect on 
invasive breast cancers. Though, they based their assumption on data collected at the patient 
level rather than the in-vitro cell based model utilized in this study. In spite of this, further 
studies are needed to elucidate the mechanisms for the anti-proliferative properties of adjuvant 
and neoadjuvant anti-telomerase approach, as well as verify and expand upon these findings. 
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